 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) traded down 3.2% during trading on Friday . The company traded as low as $39.93 and last traded at $39.98. 36,930 shares changed hands during...

Soleno Therapeutics (NASDAQ:SLNO) Stock Price Down 3.2%

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) dropped 3.2% on Friday . The stock traded as low as $39.93 and last traded at $39.98. Approximately 36,930 shares traded hands...

Soleno Therapeutics (NASDAQ:SLNO)  Shares Down 3.2%

CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)

Insider Sell: CFO James Mackaness Sells 5,175 Shares of Soleno Therapeutics Inc (SLNO)

This indicator may be signaling that SLNO's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Soleno Therapeutics (SLNO, $41.66) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

Just because a business does not make any money, does not mean that the stock will go down. For example, Soleno...

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ( Soleno ) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This price move could indicate a change in the trend, and may be a sell signal for investors...

Soleno Therapeutics (SLNO, $44.95) price exceeded its 50-day Moving Average on March 07, 2024

In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Soleno Therapeutics (SLNO Research Report), with a price t...

Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Soleno Therapeutics participates in a conference call with Piper Sandler

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Volume (M)	5.00
52-Wk High	$53.82
52-Wk Low	$3.16

SLNO Soleno Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals